Emerging studies indicate that PD‐L1/PD‐1 blockade therapy does not only affect the tumor microenvironment, but also alters the systemic dynamics of immune cell populations (Hui et al, 2017; Kamphorst et al, 2017a,b; Krieg et al, 2018). This evidence concerns the gene CD274 and neoplasm.